Literature DB >> 2659185

Kawasaki syndrome.

J W Newburger1, J C Burns.   

Abstract

Kawasaki syndrome is a leading cause of pediatric acquired heart disease in the United States. Coronary artery aneurysms or ectasia develop in approximately 15 to 25 per cent of affected children; treatment with intravenous gamma globulin in the acute phase reduces this risk three- to five-fold. Angiographic resolution occurs in approximately one half of aneurysmal arterial segments, but these show persistent histologic and functional abnormalities. The remainder may continue to be aneurysmal, often with development of progressive stenosis or occlusion. Myocarditis is a universal feature of acute Kawasaki syndrome, but the occurrence of late abnormalities of myocardial function among children without coronary artery disease is controversial. Aortic and mitral regurgitation may occur in the acute illness, and late-onset valvar regurgitation has been reported as a rare complication. Continued long-term surveillance in patients with and without detected coronary abnormalities is necessary to determine the nature history of Kawasaki syndrome with respect to coronary artery status, myocardial function, and valvar regurgitation.

Entities:  

Mesh:

Year:  1989        PMID: 2659185

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  4 in total

Review 1.  Kawasaki syndrome: lessons for Britain.

Authors:  J G Bissenden; S Hall
Journal:  BMJ       Date:  1990-04-21

Review 2.  Superantigens related to Kawasaki syndrome.

Authors:  D Y Leung
Journal:  Springer Semin Immunopathol       Date:  1996

3.  Occult Kawasaki syndrome with giant coronary artery aneurysms.

Authors:  R M Hinson; T D Schofield; J French; J G Stevenson; D Stewart; J B Kinney
Journal:  West J Med       Date:  1993-02

4.  Management of Kawasaki disease in the British Isles.

Authors:  R Dhillon; L Newton; P T Rudd; S M Hall
Journal:  Arch Dis Child       Date:  1993-12       Impact factor: 3.791

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.